Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
Karuna’s top asset is KarXT, an experimental antipsychotic with a promising novel mechanism. It’s currently being reviewed by the USFDA for treatment of schizophrenia in adults
